PharmAthene cancels merger agreement with Theraclone

PharmAthene (PIP +1.6%) terminates an agreement that called for a subsidiary to merge with Theraclone in an all-stock deal.

PIP will pay Theraclone a $1M termination fee. (PR)

From other sites
Comments (1)
  • docrog
    , contributor
    Comments (51) | Send Message
    I think this was the best move for the stockholders.The Theraclone deal appeared to be getting dirty at the expense of the stockholders.It doesn't say much good for the board of directors. They were going to cash in for a bundle. If they had their way the stock price AFTER Siga would have been 1.88! I hope we all can see how good it is to have a few big guys in the stockholders pen. Golly how come Theraclone high tailed it so fast? Dirty dealin midnight trippin???We all owe that 10% stockholder company a big vote of thanx for the heads up!!!
    3 Dec 2013, 03:01 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs